Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

SILO
Silo Pharma, Inc. Common Stock
stock NASDAQ

At Close
Oct 2, 2026 2:16:12 PM EDT
1.51USD+0.667%(+0.01)980,742
1.50Bid   1.55Ask   0.05Spread
Pre-market
Oct 2, 2026 9:14:30 AM EDT
1.51USD+0.667%(+0.01)782
After-hours
Oct 2, 2026 4:59:30 PM EDT
1.47USD-2.649%(-0.04)482,216
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Dec 14, 2021
08:07AM EST  Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, announced the engagement of Donohoe Advisory Associates LLC ("Donohoe") for consulting and advisory services in connection with the potential up-listing of Silos common shares on the NASDAQ Stock Market.   GlobeNewswire Inc
Dec 2, 2021
08:10AM EST  Silo Pharma Announces Grant of U.S. Patent For its Novel CNS   GlobeNewswire Inc
Nov 18, 2021
09:45AM EST  Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that their joint venture partner Zylo Therapeutics received its first ketamine shipment and initiated loading ketamine into their Z-Pod transdermal technology.   GlobeNewswire Inc
Nov 11, 2021
08:09AM EST  Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today reported its financial results for the third quarter 2021 and gave an update on recent progress in its business.   GlobeNewswire Inc
Oct 27, 2021
08:15AM EDT  Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that it has entered into a sponsored research agreement with Columbia University pursuant to which Silo has been granted an option to license certain assets currently under development, including Alzheimers disease.   GlobeNewswire Inc
Oct 18, 2021
01:37PM EDT  Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation   Benzinga
Oct 13, 2021
04:25PM EDT  There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are   Benzinga
Oct 7, 2021
08:11AM EDT  Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that their joint venture partner Zylo Therapeutics received approval from the DEA to advance the development of their Z-pod technology in combination with Ketamine.   GlobeNewswire Inc
Oct 6, 2021
09:27AM EDT  Alkido Pharma Trading 30% Below Cash Value Despite Positive Indications   Benzinga
Aug 25, 2021
08:01AM EDT  Silo Pharma, Inc.(OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced the filing of three distinct Patent Cooperation Treaty (PCT) patent applications pertaining to the central nervous system delivery of unique anti-inflammatory therapeutics coupled with psilocybin.   GlobeNewswire Inc
Aug 11, 2021
08:10AM EDT  Silo Pharma, Inc.(OTCQB:SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that Silos joint venture partner, ZYLO Therapeutics, completed its first inspection with the SC Board of Pharmacy and will move forward with the Department of Health and Environmental Control.   GlobeNewswire Inc
Jul 21, 2021
10:43AM EDT  Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, has announced that the company will be participating in a nationwide media tour on Thursday, July 22 from 8 a.m. 11:30 a.m. EST.   GlobeNewswire Inc
Jul 12, 2021
08:08AM EDT  Silo Pharma, Inc. (OTCQB: SILO), a development stage biopharmaceutical company, today announced that it has entered into a Scientific Research Agreement with the University of Maryland, Baltimore.   GlobeNewswire Inc
Jul 7, 2021
08:15AM EDT  Silo Pharma extends agreement for experimental Rheumatoid   GlobeNewswire Inc
Jun 29, 2021
08:00AM EDT  MCOA   GlobeNewswire Inc
Jun 8, 2021
09:36AM EDT  Silo Pharma Announces Collaboration with University California San Francisco to study Psilocybin as an Anti-Inflammatory agent in Parkinson's and Bipolar Patients   Benzinga
08:15AM EDT  Silo Pharma Announces Collaboration with University California San   GlobeNewswire Inc
May 28, 2021
03:45PM EDT  Psyched: Nasdaq Gets Its Third Psychedelics Company, Mynd Goes Public, Delic Buys New Research Facility   Benzinga
May 25, 2021
08:15AM EDT  Silo Pharma, Inc. (OTCQB: SILO) a development stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, is pleased to announce that it has submitted its initial application to list on the NASDAQ Capital Market (NASDAQ).   GlobeNewswire Inc
May 13, 2021
08:15AM EDT  Silo Pharma announces important milestone. Investigator led study   GlobeNewswire Inc
Apr 28, 2021
08:05AM EDT  Silo Pharma (SILO) and Zylo Therapeutics, Inc. (ZTI) enter into   GlobeNewswire Inc
Apr 22, 2021
08:05AM EDT  Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that its Board of Directors has unanimously voted to uplist to the NASDAQ.   GlobeNewswire Inc
Apr 7, 2021
08:01AM EDT  Silo Pharma Finalizes Sublicense Deal for its Targeted Psilocybin   GlobeNewswire Inc
Mar 23, 2021
07:00AM EDT  Psilocybin Data Study Agreement Reached Between Ehave Inc. and   GlobeNewswire Inc
Mar 4, 2021
04:38PM EST  IIROC Trade Resumption - SILO   PR Newswire
08:44AM EST  Silo Pharma, Inc. (OTC QB: SILO), a developmental stage biopharmaceutical company, today announced that it has executed an exclusive option agreement with the University of Maryland, Baltimore to explore a novel invention generally known as Joint-homing peptides for use in the investigation and treatment of arthritogenic processes.   GlobeNewswire Inc
Feb 23, 2021
08:15AM EST  Silo Pharma to Present at Proactive's One2One Virtual Investor Forum   GlobeNewswire Inc
Feb 18, 2021
08:15AM EST  Silo Pharma Licenses Novel Peptide-Guided Drug Delivery Approach   GlobeNewswire Inc
Feb 17, 2021
06:52AM EST  Aikido Pharma Slumps On $75M Upsized Equity Offering Issued At 25% Discount   Benzinga
Feb 10, 2021
08:45AM EST  Silo Pharma to pursue additional strategic partnerships and intellectual property acquisitions in the psychedelic medicine space   GlobeNewswire Inc
Jan 26, 2021
08:18AM EST  Silo Pharma Reaches Terms with University of Maryland Baltimore   GlobeNewswire Inc
Jan 19, 2021
08:13AM EST  Silo Pharma to Participate in Virtual Conference on Investing in   GlobeNewswire Inc
Jan 13, 2021
08:45AM EST  Silo Pharma Enters into Sponsored Research Agreement for Potential   GlobeNewswire Inc
Jan 11, 2021
08:32AM EST  Silo Pharma Provides Details Of Patent License Agreement For Psilocybin, Cancer Applications   Benzinga
08:30AM EST  Silo Pharma Provides Details of Patent License Agreement for   GlobeNewswire Inc
Jan 6, 2021
08:15AM EST  Silo Pharma Inc. Receives One Million Dollars in Up Front   GlobeNewswire Inc
Dec 15, 2020
08:30AM EST  Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that its Board of Directors has named clinical researcher and professor, Dr. Charles B. Nemeroff, M.D., Ph.D., to its Scientific Advisory Board.   GlobeNewswire Inc
Dec 7, 2020
08:15AM EST  Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that its Board of Directors has named behavioral health expert Dr. Peter Hendricks, Ph.D. to its newly formed Scientific Advisory Board.   GlobeNewswire Inc
Dec 4, 2020
04:52PM EST  Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that it has been requested by the OTC Markets Group (the OTC Markets) to comment on recent promotional activity.   GlobeNewswire Inc
Dec 2, 2020
08:30AM EST  Silo Pharma Announces Plans for a Phase 2B Investigator Lead Study Using Psychedelics Psilocybin and Lysergic Acid Diethylamide ("LSD") to Treat Parkinson's Disease   Business Wire
Nov 16, 2020
09:40AM EST  Silo Pharma, Inc. (OTCQB: SILO) today announced that its Board of Directors has named scientific research investigator Dr. Joshua Woolley, M.D. / Ph.D. to its newly formed Scientific Advisory Board.   GlobeNewswire Inc
Nov 12, 2020
10:20AM EST  Emerging Markets Report: Meeting the Moment   GlobeNewswire Inc
07:07AM EST  Silo Pharma, Inc. Announces Filing of Three U.S. Provisional   GlobeNewswire Inc
Nov 9, 2020
07:15AM EST  Silo Pharma, Inc. Launches Scientific Advisory Board with   GlobeNewswire Inc
Oct 14, 2020
10:06AM EDT  To Begin Trading on the OTCQB Venture Market Under the Symbol SILO Today   GlobeNewswire Inc
Oct 13, 2020
08:45AM EDT  Silo Pharma, Inc. Enters into Option Agreement with University of   GlobeNewswire Inc
Oct 6, 2020
09:55AM EDT  Silo Pharma, Inc. Expands Board with Appointment of Dr. Kevin   GlobeNewswire Inc
Sep 28, 2020
09:14AM EDT  Early Entrant, Addressing Massive Market Opportunity for Psychedelic Drug Therapies for a Wide-Range of Conditions, Including PTSD and Parkinsons Disease;   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC